Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mauro Rigato

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Diabetes, Obesity & Metabolism|August 1, 2019
Fixed versus flexible combination of GLP-1 receptor agonists with basal insulin in type 2 diabetes: A retrospective multicentre comparative effectiveness studyMario Luca Morieri, Mauro Rigato, Vera Frison, et al.
The Journal of Clinical Endocrinology and Metabolism|April 18, 2020
Effectiveness of Dulaglutide in the Real World and in Special Populations of Type 2 Diabetic PatientsMario Luca Morieri, Vera Frison, Mauro Rigato, et al.
Metabolism: Clinical and Experimental|February 29, 2020
Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studiesMario Luca Morieri, Mauro Rigato, Vera Frison, et al.
Vascular Pharmacology|December 9, 2014
Short-term statin discontinuation increases endothelial progenitor cells without inflammatory rebound in type 2 diabetic patientsGian Paolo Fadini, Mauro Rigato, Federico Boscari, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|October 11, 2021
Changes in markers of hepatic steatosis and fibrosis in patients with type 2 diabetes during treatment with glucagon-like peptide-1 receptor agonists. A multicenter retrospective longitudinal studyMario Luca Morieri, Giovanni Targher, Annunziata Lapolla, et al.
Diabetologia|August 23, 2024
Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine careGian Paolo Fadini, Enrico Longato, Mario Luca Morieri, et al.
Diabetologia|June 26, 2014
The molecular signature of impaired diabetic wound healing identifies serpinB3 as a healing biomarkerGian Paolo Fadini, Mattia Albiero, Renato Millioni, et al.
Diabetes|January 8, 2016
NETosis Delays Diabetic Wound Healing in Mice and HumansGian Paolo Fadini, Lisa Menegazzo, Mauro Rigato, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Diabetes, Obesity & Metabolism|August 1, 2019
Fixed versus flexible combination of GLP-1 receptor agonists with basal insulin in type 2 diabetes: A retrospective multicentre comparative effectiveness studyMario Luca Morieri, Mauro Rigato, Vera Frison, et al.
The Journal of Clinical Endocrinology and Metabolism|April 18, 2020
Effectiveness of Dulaglutide in the Real World and in Special Populations of Type 2 Diabetic PatientsMario Luca Morieri, Vera Frison, Mauro Rigato, et al.
Metabolism: Clinical and Experimental|February 29, 2020
Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studiesMario Luca Morieri, Mauro Rigato, Vera Frison, et al.
Vascular Pharmacology|December 9, 2014
Short-term statin discontinuation increases endothelial progenitor cells without inflammatory rebound in type 2 diabetic patientsGian Paolo Fadini, Mauro Rigato, Federico Boscari, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|October 11, 2021
Changes in markers of hepatic steatosis and fibrosis in patients with type 2 diabetes during treatment with glucagon-like peptide-1 receptor agonists. A multicenter retrospective longitudinal studyMario Luca Morieri, Giovanni Targher, Annunziata Lapolla, et al.
Diabetologia|August 23, 2024
Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine careGian Paolo Fadini, Enrico Longato, Mario Luca Morieri, et al.
Diabetologia|June 26, 2014
The molecular signature of impaired diabetic wound healing identifies serpinB3 as a healing biomarkerGian Paolo Fadini, Mattia Albiero, Renato Millioni, et al.
Diabetes|January 8, 2016
NETosis Delays Diabetic Wound Healing in Mice and HumansGian Paolo Fadini, Lisa Menegazzo, Mauro Rigato, et al.
Pageof 3